- Home
- 2021
Precision Medicine at Work
June 18, 2021Precision Medicine at work for patients with Inherited Retinal Disorders https://youtu.be/FXdHVi9szb8 Rachel Huckfeldt, MD, PhD of the Inherited Retinal Disorders (IRD) Service and the Ocular Genomics Institute, speaks about the important collaborations between... Read More
Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
June 3, 2021Caitlin CollinQin Liu At the virtual 2021 meeting of the Association for Research in Vision and Ophthalmology (ARVO), Caitlin Collin, PhD, from Mass Eye and Ear (MEE), presented a promising CRISPR/Cas9 gene-editing approach for treating people with autosomal dominant retinitis pigmentosa (adRP) caused by mutations in the gene RP1. The project... Read More
Ground-breaking study to restore vision uses CRISPR technology
May 24, 2021Eric Pierce MD PhDJason Comander MD PhD Mass Eye and Ear is co-leading a new, revolutionary clinical trial that uses CRISPR gene editing to correct a genetic mutation that leads to a form of blindness caused by Leber congenital amaurosis, an inherited retinal disorder. Clinical trial participant Michael Kalberer is the second person in the... Read More
Ocular Genomics Institute Scientists publish large Gene-Wide Association Study of Glaucoma
March 2, 2021Janey Wiggs Ayellet Segre Janey Wiggs, MD, Ph.D., Ocular Genomics Institute Associate Director, Chief of Ophthalmology Clinical Research at Mass Eye and Ear, and the Paul Austin Chandler Professor of Ophthalmology and Vice Chair of Clinical Research at Harvard Medical School, and Ayellet Segre, genetic biostatistician, Ocular Genomics... Read More
AAVCOVID Vaccine developed by Luk Vandenberghe to start Clinical trials
February 10, 2021Associate OGI Director Luk Vandenberghe and University of Pennsylvania gene therapy head James Wilson said primate safety and efficacy tests have proven promising for their single-dose candidate, targeted for room-temperature storage. The Bill & Melinda Gates Foundation has awarded the researchers up to $2.1 million to move the vaccine... Read More